» Articles » PMID: 38724690

Monomeric Compounds from Natural Products for the Treatment of Pulmonary Fibrosis: a Review

Overview
Specialty Pharmacology
Date 2024 May 9
PMID 38724690
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary fibrosis (PF) is the end stage of lung injury and chronic lung diseases that results in diminished lung function, respiratory failure, and ultimately mortality. Despite extensive research, the pathogenesis of this disease remains elusive, and effective therapeutic options are currently limited, posing a significant clinical challenge. In addition, research on traditional Chinese medicine and naturopathic medicine is hampered by several complications due to complex composition and lack of reference compounds. Natural product monomers, possessing diverse biological activities and excellent safety profiles, have emerged as potential candidates for preventing and treating PF. The effective anti-PF ingredients identified can be generally divided into flavonoids, saponins, polysaccharides, and alkaloids. Specifically, these monomeric compounds can attenuate inflammatory response, oxidative stress, and other physiopathological processes of the lung through many signaling pathways. They also improve pulmonary factors. Additionally, they ameliorate epithelial-mesenchymal transition (EMT) and fibroblast-myofibroblast transdifferentiation (FMT) by regulating multiple signal amplifiers in the lungs, thereby mitigating PF. This review highlights the significant role of monomer compounds derived from natural products in reducing inflammation, oxidative stress, and inhibiting EMT process. The article provides comprehensive information and serves as a solid foundation for further exploration of new strategies to harness the potential of botanicals in the treatment of PF.

Citing Articles

Oxidative Stress, Glutaredoxins, and Their Therapeutic Potential in Posterior Capsular Opacification.

Li C, Yan W, Yan H Antioxidants (Basel). 2024; 13(10).

PMID: 39456463 PMC: 11504336. DOI: 10.3390/antiox13101210.


Carvacrol inhibits the progression of oral submucous fibrosis via downregulation of PVT1/miR-20a-5p-mediated pyroptosis.

Yu C, Hsieh P, Chao S, Liao Y, Yu C, Chueh P J Cell Mol Med. 2024; 28(18):e70112.

PMID: 39320020 PMC: 11423347. DOI: 10.1111/jcmm.70112.


Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review.

Zhou Y, Gu C, Zhu Y, Zhu Y, Chen Y, Shi L Front Pharmacol. 2024; 15:1463140.

PMID: 39188946 PMC: 11345237. DOI: 10.3389/fphar.2024.1463140.

References
1.
Adamcakova J, Balentova S, Barosova R, Hanusrichterova J, Mikolka P, Prso K . Effects of Green Tea Polyphenol Epigallocatechin-3-Gallate on Markers of Inflammation and Fibrosis in a Rat Model of Pulmonary Silicosis. Int J Mol Sci. 2023; 24(3). PMC: 9916388. DOI: 10.3390/ijms24031857. View

2.
Agackiran Y, Gul H, Gunay E, Akyurek N, Memis L, Gunay S . The efficiency of proanthocyanidin in an experimental pulmonary fibrosis model: comparison with taurine. Inflammation. 2012; 35(4):1402-10. DOI: 10.1007/s10753-012-9453-6. View

3.
Alharbi K, Fuloria N, Fuloria S, Rahman S, Al-Malki W, Shaikh M . Nuclear factor-kappa B and its role in inflammatory lung disease. Chem Biol Interact. 2021; 345:109568. DOI: 10.1016/j.cbi.2021.109568. View

4.
Ameeramja J, Perumal E . Possible Modulatory Effect of Tamarind Seed Coat Extract on Fluoride-Induced Pulmonary Inflammation and Fibrosis in Rats. Inflammation. 2018; 41(3):886-895. DOI: 10.1007/s10753-018-0743-5. View

5.
An L, Peng L, Sun N, Yang Y, Zhang X, Li B . Tanshinone IIA Activates Nuclear Factor-Erythroid 2-Related Factor 2 to Restrain Pulmonary Fibrosis via Regulation of Redox Homeostasis and Glutaminolysis. Antioxid Redox Signal. 2018; 30(15):1831-1848. DOI: 10.1089/ars.2018.7569. View